Geron Presents Positive Results from Phase 2 Study of Imetelstat in Essential Thrombocythemia at the American Society of Hematology Annual Meeting

[at noodls] – MENLO PARK, Calif., December 10, 2012 – Geron Corporation (Nasdaq: GERN) today announced positive clinical results from the Phase 2 trial of imetelstat, the company’s first-in-class telomerase inhibitor, … more

View todays social media effects on GERN

View the latest stocks trending across Twitter. Click to view dashboard

See who Geron is hiring next, click here to view